FIELD: medicine, biochemistry, genetic engineering.
SUBSTANCE: invention reports the capacity of the human immunodeficiency virus full-scale transactivating protein (TAT-protein) and its two N-terminal fragments also consisting of 86 and 71 amino acid residues, respectively, to inhibit formation of adipose tissue in vivo. In this connection, the invention proposes using abovementioned polypeptides, among them prepared by method of recombinant DNA as an active component of pharmaceutical preparations. In particular, the invention proposes the composition for prophylaxis and treatment of obesity that comprises the full-scale TAT-protein (SEQ ID № 1) or any of its fragments (SEQ ID №2 or SEQ ID № 3) and a suitable adjuvant.
EFFECT: valuable medicinal properties of composition.
2 cl, 4 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OBESITY POLYPEPTIDE (OB) (VARIANTS), ITS ANALOGUE (VARIANTS), AND FUSED PROTEIN (VARIANTS), NUCLEIC ACID ISOLATED MOLECULE, DNA MOLECULE, CLONING RECOMBINANT VECTOR, EXPRESSION RECOMBINANT VECTOR, PHARMACEUTICAL COMPOSITION, MONOCLONAL AND POLYCLONAL ANTIBODY | 1995 |
|
RU2273645C9 |
| DERIVATIVES OF PROTEIN OB | 1996 |
|
RU2178307C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| NEW PEPTIDE INVOLVED IN ENERGY HOMEOSTASIS | 2006 |
|
RU2409590C2 |
| APPLICATION OF LEPTIN ANTAGONISTS FOR TREATMENT OF INSULIN RESISTANCE IN DIABETES MELLITUS TYPE II | 1997 |
|
RU2201249C2 |
| FAT CONTENT CONTROL | 2003 |
|
RU2346688C2 |
| CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY | 2010 |
|
RU2573896C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2593960C2 |
| METHOD FOR LEAN MUSCLE MASS GAIN AND FATTY TISSUE REDUCTION | 2007 |
|
RU2456985C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2732703C2 |
